Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 12;3(2):e000164. doi: 10.1136/bmjno-2021-000164

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CMAP decrement showed significant associations with upper limb and lower limb functions. (A) Revised Upper Limb Module score (r²=0.7631, p=0.0021), (B) 6MWT distance (r²=0.5012, p=0.0328) and (C) fatigue on the 6MWT (ratio of the distance walked during min 6 divided by the distance walked during min 1) (r²=0.6410, p=0.0095). CMAP decrement did not show a significant correlation with Hammersmith Functional Rating Scale Expanded score (r²=0.1679, p=0.2735) (not shown). R² is the square of Pearson correlation coefficients. n=9 ambulatory participants at 14 months of treatment with nusinersen (four women and five men). 6MWT, 6 min walk test; CMAP, compound muscle action potential.